Clinical trial
Tigecycline (Hai Zheng Li Xing®) Combined With Piperacillin/Tazobactam (Tazocin ®) Empirical Treatment of Severe Sepsis and Septic Shock in Patients With Abdominal Infection
NCT02191475 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tigecycline (Hai Zheng Li Xing®) Combined With Piperacillin/Tazobactam (Tazocin ®) Empirical Treatment of Severe Sepsis and Septic Shock in Patients With Abdominal Infection
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- May 31, 2014
- Completion date
- May 31, 2017
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
abdominal infection